Cachexia - Pipeline Review, H1 2017

March 2017 | 43 pages | ID: CF4632E5B24EN
Global Markets Direct

Abstracts

Cachexia - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cachexia – Pipeline Review, H1 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape.

Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis, HIV, cancer, and in individuals with age-associated „failure to thrive? syndrome. Symptoms include involuntary (unintentional) weight loss, skeletal muscle wasting, anorexia/loss of appetite, lowered quality of life. Treatment includes diet, nutritional supplements, exercise and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cachexia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cachexia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cachexia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Cachexia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cachexia (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Cachexia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cachexia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cachexia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cachexia (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cachexia (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cachexia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Cachexia – Overview
Cachexia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cachexia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cachexia – Companies Involved in Therapeutics Development
Aphios Corp
GlaxoSmithKline Plc
MYOS RENS Technology Inc
Novartis AG
Teijin Pharma Ltd
VBS Pharmaceuticals
Cachexia – Drug Profiles
ARM-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1889 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAR Peptide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLN-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2881078 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Musculoskeletal Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target Melanocortin-4 Receptor for Cachexia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cachexia – Dormant Projects
Cachexia – Discontinued Products
Cachexia – Product Development Milestones
Featured News & Press Releases
Jun 04, 2002: Aphios Receives National Cancer Institute Grant For Developing Natural Cannabinoid Products for Medical Use
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cachexia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Cachexia – Pipeline by Aphios Corp, H1 2017
Cachexia – Pipeline by GlaxoSmithKline Plc, H1 2017
Cachexia – Pipeline by MYOS RENS Technology Inc, H1 2017
Cachexia – Pipeline by Novartis AG, H1 2017
Cachexia – Pipeline by Teijin Pharma Ltd, H1 2017
Cachexia – Pipeline by VBS Pharmaceuticals, H1 2017
Cachexia – Dormant Projects, H1 2017
Cachexia – Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cachexia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Aphios Corp
GlaxoSmithKline Plc
MYOS RENS Technology Inc
Novartis AG
Teijin Pharma Ltd
VBS Pharmaceuticals